These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 22991927)

  • 1. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.
    Oh ST; Gotlib J
    Expert Rev Hematol; 2010 Jun; 3(3):323-37. PubMed ID: 21082983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 inhibition for the treatment of hematologic and solid malignancies.
    Harry BL; Eckhardt SG; Jimeno A
    Expert Opin Investig Drugs; 2012 May; 21(5):637-55. PubMed ID: 22493978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New JAK2 inhibitors for myeloproliferative neoplasms.
    Quintás-Cardama A; Verstovsek S
    Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
    Tefferi A
    Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
    Valentino L; Pierre J
    Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
    Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
    LaFave LM; Levine RL
    Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
    Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
    Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
    Meyer SC
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
    Levine RL; Wernig G
    Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
    Bhagwat N; Levine RL; Koppikar P
    Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
    Rosenthal A; Mesa RA
    Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.